血清胱抑素C与颈动脉粥样硬化相关性研究
The Relationship between Serum Cystatin C and Carotid Atherosclerosis
摘要: 目的:探讨缺血性脑血管病(Ischemic cerebrovascular disease, ICD)患者血清胱抑素C (Cystatin C, CysC)与颈动脉斑块性质及颈动脉狭窄程度的关系。方法:选取完善头颈部CT血管造影(CTA)的ICD患者128例,采用全自动生化分析仪测定其CysC水平。根据研究对象的血清CysC中位数水平将研究对象分为低CysC组(n = 66,CysC浓度≤0.95 mg/L)和高CysC组(n = 62,CysC浓度>0.95 mg/L),然后比较两组患者的颈动脉斑块性质和颈动脉狭窄程度。使用Spearman等级相关分析血清CysC水平与ICD患者颈动脉斑块性质和颈动脉狭窄程度的相关性。结果:高CysC组钙化斑块的比例较低CysC组低(χ2 = 18.636, P < 0.05),混合性斑块和脂质斑块的比例均高于低CysC组(χ2 = 7.326, P< 0.05; χ2 = 11.291, P < 0.05),差异均具有统计学意义;高CysC组和低CysC组斑块总比例差异无统计学意义(χ2 = 3.185, P > 0.05)。高CysC组轻度狭窄比例较低CysC组低(χ2 = 20.243, P < 0.05),中度、重度或闭塞比例均高于低CysC组(χ2 = 7.212, P < 0.05; χ2 = 7.819, P < 0.05),差异均具有统计学意义;高CysC组和低CysC组颈动脉狭窄总比例差异无统计学意义(χ2 = 1.671, P > 0.05)。Spearman等级相关分析显示,ICD患者颈动脉斑块稳定程度、颈动脉狭窄程度均与血清CysC呈正相关(r = 0.450, P < 0.05; r = 0.376, P < 0.05)。结论:ICD患者颈动脉斑块性质、颈动脉狭窄程度与血清CysC水平相关。高CysC水平会增加不稳定斑块发生率,加重颈动脉狭窄程度。
Abstract: Objective: To investigate the relationship between serum cystatin C (CysC) and the property of carotid plaque and the degree of carotid stenosis in patients with ischemic cerebrovascular disease (ICD). Methods: 128 patients with ICD who had completed CT angiography (CTA) of head and neck were selected and their CysC levels were measured by automatic biochemical analyzer. The subjects were divided into low CysC group (n = 66, CysC concentration ≤ 0.95 mg/L) and high CysC group (n = 62, CysC concentration > 0.95 mg/L) according to the median level of serum CysC of the subjects. Then the property of carotid plaque and the degree of carotid stenosis were compared between the two groups. Spearman grade correlation was used to analyze the correlation between serum CysC level and carotid stenosis and plaque property in ICD patients. Results: The proportion of calcified plaque in high CysC group was lower than that in low CysC group (χ2 = 18.636, P < 0.05); the proportion of mixed plaque and lipid plaque was higher than that in low CysC group (χ2 = 7.326, P < 0.05; χ2 = 11.291, P < 0.05), the difference was statistically significant. There was no significant difference in the total proportion of plaque between high CysC group and low CysC group (χ2 = 3.185, P > 0.05). The proportion of mild stenosis in high CysC group was lower than that in low CysC group (χ2 = 20.243, P< 0.05), and the proportion of moderate, severe or occlusion was higher than that in low CysC group (χ2 = 7.212, P < 0.05; χ2 = 7.819, P< 0.05), and the difference was statistically significant. The total proportion of carotid stenosis in high CysC group and low CysC group was not statistically significant (χ2 = 1.671, P > 0.05). Spearman grade correlation analysis showed that the degree of carotid plaque stability and carotid stenosis in ICD patients were positively correlated with serum CysC (r = 0.450, P < 0.05; r = 0.376, P < 0.05). Conclusion: The properties of carotid plaque and the degree of carotid stenosis were correlated with the level of serum CysC in ICD patients. High CysC level will increase the incidence of unstable plaque and aggravate the degree of carotid stenosis.
文章引用:闫柳柳, 韩迪, 郑雨, 李云法, 郭孝兹, 王燕, 耿凡琪. 血清胱抑素C与颈动脉粥样硬化相关性研究[J]. 临床医学进展, 2020, 10(6): 1049-1055. https://doi.org/10.12677/ACM.2020.106159

参考文献

[1] Wu, S.M., et al. (2019) Stroke in China: Advances and Challenges in Epidemiology, Prevention, and Management. The Lancet Neurology, 18, 394-405.
[2] Jander, S., et al. (2001) Expression of Tissue Factor in High-Grade Carotid Artery Stenosis: Association with Plaque Destabilization. Stroke, 32, 850-854. [Google Scholar] [CrossRef
[3] Goldstein, L.B., et al. (2001) Primary Prevention of Ischemic Stroke: A Statement for Healthcare Professionals from the Stroke Council of the American Heart Association. Circulation, 103, 163-182. [Google Scholar] [CrossRef
[4] Wali, U., et al. (2019) Comparison of Serum Levels of Cystatin-C and Traditional Renal Biomarkers for the Early Detection of Pre-Hypertensive Nephropathy. The Journal of the Pakistan Medical Association, 69, 313-319.
[5] Urbonaviciene, G., et al. (2011) Higher Cystatin C Level Predicts Long-Term Mortality in Patients with Peripheral Arterial Disease. Atherosclerosis, 216, 440-445. [Google Scholar] [CrossRef] [PubMed]
[6] Luo, J., et al. (2015) Cystatin C and Cardiovascular or All-Cause Mortality Risk in the General Population: A Meta-Analysis. Clinica Chimica Acta, 450, 39-45. [Google Scholar] [CrossRef] [PubMed]
[7] Doganer, Y.C., et al. (2013) Relationship of Cystatin C with Coronary Artery Disease and Its Severity. Coronary Artery Disease, 24, 119-126. [Google Scholar] [CrossRef
[8] Kaneko, R., et al. (2018) Serum Cystatin C Level Is Associated with Carotid Arterial Wall Elasticity in Subjects with Type 2 Diabetes Mellitus: A Potential Marker of Early-Stage Atherosclerosis. Diabetes Research and Clinical Practice, 139, 43-51. [Google Scholar] [CrossRef] [PubMed]
[9] 吴江, 杨弋, 饶明俐. 中国脑血管疾病分类2015 [J]. 中华神经科杂志, 2017, 50(3): 168-171.
[10] Ren, J., Dong, X. and Nao, J. (2020) Serum Cystatin C Is Associated with Carotid Atherosclerosis in Patients with Acute Ischemic Stroke. Neurological Sciences. [Google Scholar] [CrossRef] [PubMed]
[11] 中华医学会外科学分会血管外科学组. 颈动脉狭窄诊治指南[J]. 中国血管外科杂志(电子版), 2017, 9(3): 169-175.
[12] Saba, L., et al. (2009) Multidetector Row CT of the Brain and Carotid Artery: A Correlative Analysis. Clinical Radiology, 64, 767-778. [Google Scholar] [CrossRef] [PubMed]
[13] Randolph, S.A. (2016) Ischemic Stroke. Workplace Health & Safety, 64, 444. [Google Scholar] [CrossRef] [PubMed]
[14] Krasteva, M.P., et al. (2020) Intracranial Atherosclerotic Stenoses: Pathophysiology, Epidemiology, Risk Factors and Current Therapy Options. Advances in Therapy, 37, 1829-1865. [Google Scholar] [CrossRef] [PubMed]
[15] Xu, Y., et al. (2015) Cystatin C Is a Disease-Associated Protein Subject to Multiple Regulation. Immunology and Cell Biology, 93, 442-451. [Google Scholar] [CrossRef] [PubMed]
[16] Fatemi, S., et al. (2019) Copeptin, B-Type Natriuretic Peptide and Cystatin C Are Associated with Incident Symptomatic PAD. Biomarkers, 24, 615-621. [Google Scholar] [CrossRef
[17] Zhang, Y. and Sun, L. (2017) Cystatin C in Cerebrovascular Disorders. Current Neurovascular Research, 14, 406-414. [Google Scholar] [CrossRef] [PubMed]
[18] GP, S., et al. (1999) Cystatin C Deficiency in Human Atherosclerosis and Aortic Aneurysms. The Journal of Clinical Investigation, 104, 1191-1197. [Google Scholar] [CrossRef
[19] Salgado, J.V., Souza, F.L. and Salgado, B.J. (2013) How to Understand the Association between Cystatin C Levels and Cardiovascular Disease: Imbalance, Counterbalance, or Consequence? Journal of Cardiology, 62, 331-335. [Google Scholar] [CrossRef] [PubMed]
[20] Lafarge, J.C., et al. (2010) Cathepsins and Cystatin C in Atherosclerosis and Obesity. Biochimie, 92, 1580-1586. [Google Scholar] [CrossRef] [PubMed]
[21] Li, W., et al. (2016) Autophagy Dysfunction and Regulatory Cystatin C in Macrophage Death of Atherosclerosis. Journal of Cellular and Molecular Medicine, 20, 1664-1672. [Google Scholar] [CrossRef] [PubMed]
[22] Bengtsson, E., et al. (2005) Lack of the Cysteine Protease Inhibitor Cystatin C Promotes Atherosclerosis in Apolipoprotein E-Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 25, 2151-2156. [Google Scholar] [CrossRef
[23] 陈艳, 等. 血清胱抑素C、同型半胱氨酸与颈动脉不稳定斑块相关性的研究进展[J]. 中国当代医药, 2020, 27(1): 24-27.
[24] Yang, B., et al. (2015) Cystatin C Is an Independent Risk Factor and Therapeutic Target for Acute Ischemic Stroke. Neurotoxicity Research, 28, 1-7. [Google Scholar] [CrossRef] [PubMed]
[25] Wang, Y., et al. (2019) Association between Cystatin C and the Risk of Ischemic Stroke: A Systematic Review and Meta-Analysis. Journal of Molecular Neuroscience, 69, 444-449. [Google Scholar] [CrossRef] [PubMed]
[26] Huang, G.X., et al. (2016) Association between Serum Cystatin C Levels and the Severity or Potential Risk Factors of Acute Ischemic Stroke. Neurological Research, 38, 518-523. [Google Scholar] [CrossRef] [PubMed]
[27] Yang, S., et al., (2016) Association between Serum Cystatin C Level and Total Magnetic Resonance Imaging Burden of Cerebral Small Vessel Disease in Patients with Acute Lacunar Stroke. Journal of Stroke and Cerebrovascular Diseases, 26, 186-191. [Google Scholar] [CrossRef] [PubMed]
[28] Fang, Z., et al. (2019) Neuroprotective Autophagic Flux Induced by Hyperbaric Oxygen Preconditioning Is Mediated by Cystatin C. Neuroscience Bulletin, 35, 336-346. [Google Scholar] [CrossRef] [PubMed]
[29] Wang, Y., et al. (2019) Determination of Clinical Cut-Off Values for Serum Cystatin C Levels to Predict Ischemic Stroke Risk. Journal of Stroke and Cerebrovascular Diseases, 28, Article ID: 104345. [Google Scholar] [CrossRef] [PubMed]
[30] Dong, X. and Nao, J. (2019) Cystatin C as an Index of Acute Cerebral Infraction Recurrence: One-Year Follow-Up Study. International Journal of Neuroscience, 129, 36-41. [Google Scholar] [CrossRef] [PubMed]
[31] Fang, Z., et al. (2017) Cystatin C Is a Crucial Endogenous Protective Determinant against Stroke. Stroke, 48, 436-444. [Google Scholar] [CrossRef